Drug intelligence / Profile preview

CPH

Development stage
Preclinical
Lead developer
Merck
Modality
Hydrogel Systems → Drug Delivery Systems, Small Molecules, Peptides
Administration
Oral, Intravenous, Intramuscular
01

Overview

CPH is a non-specific abbreviation used in clinical and scientific literature to refer to several distinct substances. Most commonly in a pharmaceutical context, it refers to **cyproheptadine**, a first-generation antihistamine and serotonin antagonist used for allergic conditions, appetite stimulation, and the management of serotonin syndrome; it is also being investigated for motor recovery in chronic spinal cord injury. Additionally, CPH refers to **chicken protein hydrolysate**, a dietary supplement composed of bioactive peptides studied for its potential to reduce abdominal obesity and improve metabolic health. In agricultural and oncological research, CPH denotes **cocoa pod husk**, a natural extract rich in polyphenols being evaluated for anticancer activity against hepatocellular carcinoma. Finally, CPHs is a frequent shorthand for the **cephalosporin** class of beta-lactam antibiotics.

Brand names
Periactin
Other names
cyproheptadinechicken protein hydrolysatecocoa pod huskcephalosporins
02

Targets

HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)mAChR (Muscarinic acetylcholine receptors)HRH1 (Histamine H1 Receptor)HTR2B (5-Hydroxytryptamine Receptor 2B)

Beyond the preview

Go deeper on CPH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPH.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call